Abstract
Objectives
To evaluate PI-RADSv2 for predicting pathological downgrading after radical prostatectomy (RP) in patients with biopsy-proven Gleason score (GS) 7(3+4) PC.
Methods
A total of 105 patients with biopsy-proven GS 7(3+4) PC who underwent multiparametric prostate MRI followed by RP were included. Two radiologists assigned PI-RADSv2 scores for each patient. Preoperative clinicopathological variables and PI-RADSv2 scores were compared between patients with and without downgrading after RP using the Wilcoxon rank sum test or Fisher’s exact test. Logistic regression analyses with Firth’s bias correction were performed to assess their association with downgrading.
Results
Pathological downgrading was identified in ten (9.5 %) patients. Prostate-specific antigen (PSA), PSA density, percentage of cores with GS 7(3+4), and greatest percentage of core length (GPCL) with GS 7(3+4) were significantly lower in patients with downgrading (p = 0.002-0.037). There was no significant difference in age and clinical stage (p = 0.537-0.755). PI-RADSv2 scores were significantly lower in patients with downgrading (3.8 versus 4.4, p = 0.012). At univariate logistic regression analysis, PSA, PSA density, and PI-RADSv2 scores were significant predictors of downgrading (p = 0.003-0.022). Multivariate analysis revealed only PSA density and PI-RADSv2 scores as independent predictors of downgrading (p = 0.014-0.042).
Conclusions
The PI-RADSv2 scoring system was an independent predictor of pathological downgrading after RP in patients with biopsy-proven GS 7(3+4) PC.
Key points
• PI-RADSv2 was an independent predictor of downgrading in biopsy-proven GS 7(3+4) PC
• PSA density was also an independent predictor of downgrading
• MRI may assist in identifying AS candidates in biopsy-proven GS 7(3+4) PC patients
Similar content being viewed by others
Abbreviations
- AS:
-
Active surveillance
- CI:
-
Confidence intervals
- DCE-MRI:
-
Dynamic contrast-enhanced MRI
- DWI:
-
Diffusion-weighted imaging
- GPCL:
-
Greatest percentage of involved core length
- GS:
-
Gleason score
- MRI:
-
Magnetic resonance imaging
- OR:
-
Odds ratio
- PC:
-
Prostate cancer
- PI-RADS:
-
Prostate Imaging-Reporting and Data System
- PSA:
-
Prostate-specific antigen
- T1WI:
-
T1-weighted image
- T2WI:
-
T2-weighted image
- v2:
-
Version 2
References
Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101
Eggener SE, Mueller A, Berglund RK et al (2013) A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 189:S19–S25
Tosoian JJ, Trock BJ, Landis P et al (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29:2185–2190
Lawrentschuk N, Klotz L (2011) Active surveillance for low-risk prostate cancer: an update. Nat Rev Urol 8:312–320
Cooperberg MR, Cowan JE, Hilton JF et al (2011) Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 29:228–234
Bul M, van den Bergh RC, Zhu X et al (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110:1672–1677
Djavan B, Ravery V, Zlotta A et al (2001) Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166:1679–1683
Gondo T, Hricak H, Sala E et al (2014) Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3+4 prostate cancer. Eur Radiol 24:3161–3170
Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61:1019–1024
Gondo T, Poon BY, Matsumoto K, Bernstein M, Sjoberg DD, Eastham JA (2015) Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3+4 prostate cancer. BJU Int 115:81–86
Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746–757
Barrett T, Turkbey B, Choyke PL (2015) PI-RADS version 2: what you need to know. Clin Radiol. doi:10.1016/j.crad.2015.06.093
Muller BG, Shih JH, Sankineni S et al (2015) Prostate cancer: interobserver agreement and accuracy with the revised prostate imaging reporting and data system at multiparametric MR imaging. Radiology. doi:10.1148/radiol.2015142818:142818
Vargas HA, Hotker AM, Goldman DA et al (2015) Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol. doi:10.1007/s00330-015-4015-6
Bjurlin MA, Carter HB, Schellhammer P et al (2013) Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol 189:2039–2046
Firth D (1993) Bias reduction of maximum likelihood estimates. Biometrika 80:27–38
Paul P, Pennell ML, Lemeshow S (2013) Standardizing the power of the Hosmer-Lemeshow goodness of fit test in large data sets. Stat Med 32:67–80
Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI (2012) Do adenocarcinomas of the prostate with Gleason score (GS) </=6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 36:1346–1352
Ellis CL, Walsh PC, Partin AW, Epstein JI (2013) Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy. BJU Int 111:E306–E309
Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S (2012) The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol 188:2219–2224
Pan CC, Potter SR, Partin AW, Epstein JI (2000) The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 24:563–569
Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243:28–53
Woo S, Cho JY, Kim SY, Kim SH (2015) Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging. AJR Am J Roentgenol 204:W168–W175
Kosaka T, Mizuno R, Shinojima T et al (2014) The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men </= 50 years. Am J Clin Exp Urol 2:332–336
Woo S, Cho JY, Kim SY, Kim SH (2015) Periprostatic fat thickness on MRI: correlation with Gleason score in prostate cancer. AJR Am J Roentgenol 204:W43–W47
Gancarczyk KJ, Wu H, McLeod DG et al (2003) Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 61:589–595
Chang DT, Challacombe B, Lawrentschuk N (2013) Transperineal biopsy of the prostate—is this the future? Nat Rev Urol 10:690–702
Acknowledgments
The scientific guarantor of this publication is Jeong Yeon Cho. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. One of the authors (JL) has significant statistical expertise. Institutional Review Board approval was obtained. Written informed consent was waived by the Institutional Review Board. Some study subjects or cohorts have been previously reported in [21]: Woo S, Cho JY, Kim SY, Kim SH (2015) Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging. AJR Am J Roentgenol 204:W168-175 and [23] Woo S, Cho JY, Kim SY, Kim SH (2015) Periprostatic fat thickness on MRI: correlation with Gleason score in prostate cancer. AJR Am J Roentgenol 204:W43-47. Methodology: retrospective, cross-sectional study, performed at one institution.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Woo, S., Kim, S.Y., Lee, J. et al. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer. Eur Radiol 26, 3580–3587 (2016). https://doi.org/10.1007/s00330-016-4230-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-016-4230-9